AU2019339260B2 - Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis - Google Patents

Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis Download PDF

Info

Publication number
AU2019339260B2
AU2019339260B2 AU2019339260A AU2019339260A AU2019339260B2 AU 2019339260 B2 AU2019339260 B2 AU 2019339260B2 AU 2019339260 A AU2019339260 A AU 2019339260A AU 2019339260 A AU2019339260 A AU 2019339260A AU 2019339260 B2 AU2019339260 B2 AU 2019339260B2
Authority
AU
Australia
Prior art keywords
peptide
administration
lung
amino acid
aaegkasfttftvtkgsaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019339260A
Other languages
English (en)
Other versions
AU2019339260A1 (en
Inventor
Dale Christensen
John J. Koleng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rein Therapeutics Inc
Original Assignee
Rein Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rein Therapeutics Inc filed Critical Rein Therapeutics Inc
Publication of AU2019339260A1 publication Critical patent/AU2019339260A1/en
Assigned to LUNG THERAPEUTICS, LLC reassignment LUNG THERAPEUTICS, LLC Amend patent request/document other than specification (104) Assignors: LUNG THERAPEUTICS, INC.
Assigned to REIN THERAPEUTICS, INC. reassignment REIN THERAPEUTICS, INC. Request for Assignment Assignors: LUNG THERAPEUTICS, LLC
Application granted granted Critical
Publication of AU2019339260B2 publication Critical patent/AU2019339260B2/en
Priority to AU2025234225A priority Critical patent/AU2025234225A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019339260A 2018-09-10 2019-09-10 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis Active AU2019339260B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025234225A AU2025234225A1 (en) 2018-09-10 2025-09-19 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728997P 2018-09-10 2018-09-10
US62/728,997 2018-09-10
PCT/US2019/050332 WO2020055812A1 (en) 2018-09-10 2019-09-10 Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025234225A Division AU2025234225A1 (en) 2018-09-10 2025-09-19 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Publications (2)

Publication Number Publication Date
AU2019339260A1 AU2019339260A1 (en) 2021-03-25
AU2019339260B2 true AU2019339260B2 (en) 2025-06-26

Family

ID=69778115

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019339260A Active AU2019339260B2 (en) 2018-09-10 2019-09-10 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
AU2025234225A Pending AU2025234225A1 (en) 2018-09-10 2025-09-19 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025234225A Pending AU2025234225A1 (en) 2018-09-10 2025-09-19 Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Country Status (9)

Country Link
US (4) US11905336B2 (enExample)
EP (1) EP3849580A4 (enExample)
JP (3) JP7496826B2 (enExample)
KR (2) KR102958241B1 (enExample)
CN (2) CN121159628A (enExample)
AU (2) AU2019339260B2 (enExample)
BR (1) BR112021004404A2 (enExample)
CA (2) CA3111563A1 (enExample)
WO (1) WO2020055812A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148263A (ko) 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
WO2021216659A1 (en) * 2020-04-21 2021-10-28 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
EP4168031A4 (en) * 2020-06-19 2024-07-10 Lung Therapeutics, LLC MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG LESION
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
US20250041383A1 (en) * 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
JP2024539242A (ja) * 2021-10-22 2024-10-28 ラング セラピューティクス，エルエルシー 慢性腎疾患の治療のための改変カベオリン－１ペプチド
EP4554605A4 (en) * 2022-07-12 2026-06-17 Rein Therapeutics Inc MODIFIED CAVELOIN-1 PEPTIDE FORMULATIONS AND THEIR METHODS OF MANUFACTURING AND USING
CN119661656B (zh) * 2024-11-20 2026-05-15 华中科技大学同济医学院附属梨园医院 一种靶向拮抗pCAV1的多肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
WO2002020768A2 (en) * 2000-09-08 2002-03-14 Yale University Caveolin peptides and their use as therapeutics
US20130224163A1 (en) * 2010-11-05 2013-08-29 Brian P. Head Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2015080980A2 (en) * 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021387A (en) 1975-11-19 1977-05-03 President And Fellows Of Harvard College Eosinophilotactic tetrapeptides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4613676A (en) 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
ZA846192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
DK53291D0 (da) 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
US6540154B1 (en) 1991-04-24 2003-04-01 Aerogen, Inc. Systems and methods for controlling fluid feed to an aerosol generator
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US5277175A (en) 1991-07-12 1994-01-11 Riggs John H Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir
GB9120005D0 (en) 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
US5355872B1 (en) 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
EP0945504A3 (en) 1992-12-11 1999-12-08 The University Of Florida Materials and method for control of pests
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5797389A (en) 1995-09-06 1998-08-25 Ryder; Steven L. Variable oxygen concentration high-flow nebulizer
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
ES2140998B1 (es) 1996-05-13 2000-10-16 Univ Sevilla Procedimiento de atomizacion de liquidos.
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US20030113271A1 (en) 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
IT1291122B1 (it) 1997-03-28 1998-12-29 Sar Spa Micropompa per la nebulizzazione di fluidi con valvola dosatrice perfezionata
US6096707A (en) 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6044841A (en) 1997-08-29 2000-04-04 1263152 Ontario Inc. Breath actuated nebulizer with valve assembly having a relief piston
US6041776A (en) 1998-05-14 2000-03-28 Briggs, Iii; Stephen W. Medical nebulization device
US6354516B1 (en) 1999-11-02 2002-03-12 Aradigm Corporation Pore structures for reduced pressure aerosolization
SE9900369D0 (sv) 1999-02-04 1999-02-04 Siemens Elema Ab Ultrasonic nebuliser
US6328030B1 (en) 1999-03-12 2001-12-11 Daniel E. Kidwell Nebulizer for ventilation system
AU2001280917A1 (en) 2000-08-02 2002-02-13 Research Development Foundation Jet nebulizer assembly for home administration of drugs in aerosols
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
WO2003057291A1 (en) 2002-01-07 2003-07-17 Aerogen, Inc. Devices and methods for nebulizing fluids for inhalation
JP4761709B2 (ja) 2002-01-15 2011-08-31 エアロジェン，インコーポレイテッド エアロゾル発生器を作動するための方法およびシステム
US7332469B2 (en) 2002-04-05 2008-02-19 Board Of Regents The University Of Texas System Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
EP1501479A1 (en) 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
US20040175384A1 (en) 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005092301A1 (en) 2004-03-26 2005-10-06 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
NZ563360A (en) 2005-05-25 2011-04-29 Aerogen Inc Aerosolising liquid using an apertured membrane aligned within a peizoelectric ring
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
JP2010506860A (ja) * 2006-10-19 2010-03-04 アンジオケム，インコーポレーテッド Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
US20090068258A1 (en) 2007-08-28 2009-03-12 Lisanti Michael P Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy
EP2220115A2 (en) 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
WO2009152453A2 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
WO2010132864A1 (en) 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
MX2012003171A (es) 2009-09-28 2012-04-11 Hoffmann La Roche Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
SI2533761T1 (sl) 2010-02-11 2019-08-30 Ablynx N.V. Postopki in sestavki za pripravo aerosolov
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
KR20180092324A (ko) 2013-03-13 2018-08-20 포레스트 래보러토리즈 홀딩스 리미티드 미분화된 약제학적 조성물
KR20230148263A (ko) 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
CN104274827B (zh) 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
EP3065705A4 (en) 2013-11-04 2017-10-18 Board of Regents, The University of Texas System Compositions and methods for administration of an enzyme to a subject's airway
US9908915B2 (en) * 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
KR101845590B1 (ko) * 2015-09-25 2018-04-05 단국대학교 천안캠퍼스 산학협력단 유전자를 이용한 폐암 예후예측용 조성물
CN107216394B (zh) * 2017-06-21 2020-10-09 江南大学 一种小窝蛋白-1脚手架区融合多肽的制备方法及其应用
US20190224243A1 (en) 2018-01-25 2019-07-25 Musc Foundation For Research Development Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2020055824A1 (en) 2018-09-10 2020-03-19 Board of Regents, The University of the Texas System Dry powder formulation of caveolin-1 peptides and methods of use thereof
US20240082342A1 (en) 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
WO2020106922A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
CN111671886B (zh) 2020-03-05 2022-11-15 上海甘翼生物医药科技有限公司 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途
WO2021216659A1 (en) 2020-04-21 2021-10-28 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
EP4168031A4 (en) 2020-06-19 2024-07-10 Lung Therapeutics, LLC MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG LESION
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
US12449810B2 (en) 2021-03-01 2025-10-21 The Boeing Company Autonomous maneuver generation to mate connectors
US20250041383A1 (en) 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
JP2024539242A (ja) 2021-10-22 2024-10-28 ラング セラピューティクス，エルエルシー 慢性腎疾患の治療のための改変カベオリン－１ペプチド

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
WO2002020768A2 (en) * 2000-09-08 2002-03-14 Yale University Caveolin peptides and their use as therapeutics
US20130224163A1 (en) * 2010-11-05 2013-08-29 Brian P. Head Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2015080980A2 (en) * 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARBUZOVA, A. et al., BIOCHEM. 2000, v. 39(33), p10330-10339 *

Also Published As

Publication number Publication date
US20230212223A1 (en) 2023-07-06
JP2022500078A (ja) 2022-01-04
CN112739367B (zh) 2025-06-06
US20210347820A1 (en) 2021-11-11
WO2020055812A1 (en) 2020-03-19
US11905336B2 (en) 2024-02-20
JP2025184877A (ja) 2025-12-18
US20260062444A1 (en) 2026-03-05
US11787838B2 (en) 2023-10-17
EP3849580A4 (en) 2022-06-15
KR20210084453A (ko) 2021-07-07
AU2019339260A1 (en) 2021-03-25
CN121159628A (zh) 2025-12-19
JP7737492B2 (ja) 2025-09-10
BR112021004404A2 (pt) 2021-08-03
EP3849580A1 (en) 2021-07-21
AU2025234225A1 (en) 2025-10-09
CA3111563A1 (en) 2020-03-19
CA3311638A1 (en) 2026-06-21
US20240018186A1 (en) 2024-01-18
CN112739367A (zh) 2021-04-30
KR20260061289A (ko) 2026-05-06
JP2024071397A (ja) 2024-05-24
US12497431B2 (en) 2025-12-16
KR102958241B1 (ko) 2026-04-30
JP7496826B2 (ja) 2024-06-07

Similar Documents

Publication Publication Date Title
US12497431B2 (en) Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
US12280089B2 (en) Dry powder formulation of caveolin-1 peptides and methods of use thereof
US20250268977A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
US20230226149A1 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
WO2021216659A1 (en) Modified peptide fragments of cav-1 protein and uses thereof
US20250041383A1 (en) Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) Modified caveolin-1 peptides for the treatment of chronic kidney disease
US20250144205A1 (en) Compositions and methods for treating infectious diseases

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: REIN THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): LUNG THERAPEUTICS, LLC

FGA Letters patent sealed or granted (standard patent)